More importantly, such findings indicate that, immune checkpoint antibody treatments, such as nivolumab (anti‐PD1 antibody) and ipilimumab (anti‐CTLA‐4 antibody),42 will bring more therapeutic benefit to the high‐risk HCC cases than to low‐risk counterparts, thus leading to superior outcomes. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.